A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery

BACKGROUND: While loteprednol etabonate ophthalmic gel 0.5% (LE gel) is approved for treatment of postoperative ocular inflammation and pain, there have been no reported studies in patients undergoing laser-assisted in situ keratomileusis (LASIK) or photorefractive keratectomy (PRK). METHODS: This w...

Descripción completa

Detalles Bibliográficos
Autores principales: Salinger, Clifford L, Gordon, Michael, Jackson, Mitchell A, Perl, Theodore, Donnenfeld, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644184/
https://www.ncbi.nlm.nih.gov/pubmed/26609219
http://dx.doi.org/10.2147/OPTH.S94332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644184/
https://www.ncbi.nlm.nih.gov/pubmed/26609219
http://dx.doi.org/10.2147/OPTH.S94332

Ejemplares similares